EyePoint, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E drug delivery technology for sustained intraocular drug delivery. Its lead product candidate, DURAVYU, combines vorolanib, a selective tyrosine kinase inhibitor, with Durasert E technology to treat vascular endothelial growth factor (VEGF) mediated retinal diseases. DURAVYU is currently in Phase 3 clinical trials for wet age-related macular degeneration and diabetic macular edema. An additional pipeline program, EYP-2301, features razuprotafib, a TIE-2 agonist, formulated in Durasert E. The company operates a commercial manufacturing facility in Northbridge, Massachusetts, to support potential commercial launch.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage eyepoint.bio
Sector Healthcare IR page investors.eyepoint.bio
Tags
retinal diseases, sustained-release drug delivery, ophthalmology, age-related macular degeneration, diabetic macular edema, tyrosine kinase inhibitors, intravitreal injection, Durasert E, DURAVYU, vorolanib, EYP-2301, razuprotafib, LUGANO, LUCIA, COMO, CAPRI, DAVIO, DAVIO 2, VERONA, Durasert
Press page —

Metrics

Valuation  
Market cap $ 296.821M
Market cap (USD) $ 296.821M
P/E -0.82
PEG —
P/BV 2.74
P/S 115.14
P/OCF -1.01
P/FCF -0.99
Dividend yield —
Turnover / mcap —
Returns  
ROE -72.2%
ROI -103.1%
ROIC -81.1%
Profit margin -739.4%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 6
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007
Revenue 31.371M 43.273M 46.018M 41.404M 36.939M 34.437M 20.365M 2.961M 7.539M 1.62M 26.565M 3.473M 2.143M 3.526M 4.965M 12.162M 3.476M —
Net profit -231.962M -130.87M -70.795M -102.254M -58.417M -45.394M -56.793M -53.171M -18.485M -21.547M 6.347M -13.355M -11.9M -24.835M -8.628M -2.511M -75.67M -81.203M
Free cash flow -243.39M -130.278M -1.608M -67.155M -50.253M -14.797M -56.912M -22.015M -20.637M -16.429M 10.136M -10.919M -8.813M -9.406M -3.303M -8.631M -5.415M -21.423M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007
Share price 18.27 7.45 23.11 3.5 12.24 6.58 1.55 2.08 — — — — — — — — — —
Price performance 12m 1.45 -0.68 5.6 -0.71 0.86 3.24 -0.18 — — — — — — — — — — —

Filed figures

Figure Dec 2017 Jun 2018 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — — 0.00 10.5M 0.00 — —
Borrowings, non-current (USD) — 17.3M 17.6M 47.2M 38M 36.6M 29.3M — — —
Lease liabilities (USD) — — 0.00 3.38M 3.09M 2.68M 6.56M 5.47M 23.1M 22.8M
Cash and deposits (USD) 12.9M 38.8M 45.3M 22.2M 44.9M 179M 95.6M 281M 99.7M 102M
Intangible assets (USD) 0.00 31.4M 30.1M 27.7M 25.2M 22.7M 0.00 — — —
Right-of-use assets (USD) — — 0.00 3.08M 2.61M 2.25M 6.04M 4.98M 21M 20.2M
Net debt (borrowings + leases - cash) (USD) — -21.5M -27.6M 28.4M -3.84M -139M -49.3M -276M — —
Cash flow detail
Operating cash flow (USD) — -21.9M — -56.7M -14.4M -50.1M -65M 1.88M -126M -240M
Purchases of property, plant and equipment (USD) — -108,000 — -213,000 -362,000 -156,000 -2.15M -3.48M -4.05M -3.28M
Change in inventories (cash effect) (USD) — 0.00 — -1.86M -3.2M 1.35M -760,000 -1.55M 1.6M 492,000
Change in payables (cash effect) (USD) — 1.75M — — — — — — — —
Interest paid (cash effect) (USD) — -258,000 — -4.87M -5.51M -4.85M -2.6M -1.41M 0.00 —
Income taxes paid (cash effect) (USD) — — — — — — — — -100,000 -200,000
Share-based compensation (USD) — 2.7M — 4.57M 5.55M 7.45M 14.2M 12.1M 36.7M 27.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -22M — -56.9M -14.8M -50.3M -67.2M -1.61M -130M -243M
Income detail
Research and development expense (USD) — 16.2M 18.5M 15.4M 17.4M 28.5M 49.6M 64.7M 133M 221M
↳ 5y CAGR +18.2% +28.4% +54.0% +66.2%
Total comprehensive income (USD) — -53.2M — -56.8M -45.4M -58.4M -102M -70.7M -131M -232M
Comprehensive income to owners (USD) — -53.2M — -56.8M -45.4M -58.4M -102M -70.7M -131M -232M
Reported Feb 8, 2018 Mar 18, 2019 Mar 16, 2020 Mar 16, 2020 Mar 12, 2021 May 6, 2022 Mar 10, 2023 Mar 8, 2024 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Organizational focus on DURAVYUTM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 –

– DURAVYU DME program supported by the positive Phase 2 VERONA trial and multi-MOA activity blocking both VEGF and inflammatory IL-6 pathways involved in disease pathogenesis –

– Strategic prioritization expected to generate $30 million in annualized savings –

– $118 million in cash, cash equivalents and short-term investments, as of September 30, 2026 –

WATERTOWN, Mass., November 12, 2026 (GLOBE NEWSWIRE) – EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the third quarter ended September 30, 2026, and highlighted recent corporate developments.

“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing.

Nov 6, 2026

PDF Version

WATERTOWN, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company will participate at the following upcoming conferences:

  • Guggenheim 3rdAnnual Healthcare Innovation Conference Forum: Fireside Chat Date: November 9, 2026 Time: 2:30 pm EST

  • Stifel 2026 Healthcare Conference Forum: Fireside Chat Date: November 10, 2026 Time: 1:20 pm EST

  • Jefferies 2026 Global Healthcare Conference in London Forum: Fireside Chat Date: November 16, 2026 Time: 3:00 pm GMT

  • UBS Global Biopharma Conference 2026 Forum: Fireside Chat Date: November 17, 2026 Time: 8:40 am GMT

A webcast and subsequent archived replay of each fireside chat at the Investor Conferences may be accessed via the Investors section of the Company website at www.eyepoint.bio.

Scientific Meetings

EyePoint will be participating at the following scientific meetings:

Eyenovate at FLORetina

  • **Presentation:**LUCIA Pivotal Phase 3 Trial Results: Primary Efficacy and Safety of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD **Presenter:**Anat Loewenstein, M.D. **Date & Time (Session):**December 3, 2026 | 9:40 AM CET (Session 2 – The Hunt for a Durable wAMD Treatment) **Panel Discussion:**The Near and Far Future of Wet AMD Treatment: Durability, New Treatment Pathways, Combines Therapies with Ramiro Ribeiro, M.D., Ph.D.

  • **Presentation:**Significance of IL-6 Inhibition in DME and Update on Phase 3 COMO/CAPRI Trials **Presenter:**Ramiro Ribeiro, M.D., Ph.D. **Date & Time (Session):**December 3, 2026 | 11:15 AM CET (Session 3 – Vascular/Diabetic Retinal Diseases: New Associations and Treatments) Panel Discussion: From Controlling Neovascularization to Restoring Vascular Function with Ramiro Ribeiro, M.D., Ph.D.

FLORetina-ICOOR 2026 Congress

  • **Presentation:**EYP-1901 in the Management of Macular Disease **Presenter:**Tarek S. Hassan, M.D. **Date & Time (Session):**December 4, 2026 | 3:45 PM CET (ASRS Session – US Retinal Therapies, Update from ASRS: Durable and Sustained Treatments for Neovascular AMD)

  • **Presentation:**Bioerodible EYP-1901 (vorolanib intravitreal insert) for Diabetic Macular Edema: Overview of COMO and CAPRI Pivotal Phase 3 Trials **Presenter:**David S. Boyer, M.D. **Date & Time (Session):**December 4, 2026 | 4:30 PM CET (DME & Diabetic Retinopathy – Retina Futura Spotlight: Medical Treatment)

  • **Presentation:**LUCIA Pivotal Phase 3 Trial Efficacy and Safety Results of Bioerodible EYP-1901 (vorolanib intravitreal insert) in Wet AMD **Presenter:**Charles C. Wykoff, M.D. **Date & Time (Session):**December 5, 2026 | 12:00 PM CET (Neovascular AMD Treatment – Retina Futura Spotlight)

Presentations from these meetings will be available in the Scientific Publications section of the Company website at www.eyepoint.bio after each event.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors & Media:

Robin Garner VP, Corporate Communications & Investor Relations [email protected]

Primary Logo

Nov 5, 2026

PDF Version

WATERTOWN, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, November 12, 2026 to report its third quarter 2026 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/4ke9q689. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepoint.bio. A webcast replay will also be available on the Company website at the conclusion of the call.

About EyePoint

EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).

The Company is committed to partnering with the retinal community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.

Investors & Media:

Robin Garner VP, Corporate Communications & Investor Relations [email protected]

Primary Logo

Prompts

EyePoint, Inc. (ticker EYPT), listed in United States.

Company History

Date Change Detail
Dec 8, 2025 Renamed EYEPOINT PHARMACEUTICALS, INC. → EYEPOINT, INC.
Apr 2, 2018 Renamed PSIVIDA CORP. → EYEPOINT PHARMACEUTICALS, INC.

ETFs Holding EyePoint, Inc.

ETF Weight in ETF Shares Market value As of
FSCC 0.08% 64,020 $ 288.09K Aug 31, 2026
FESM 0.00% 18,569 $ 265.537K Jun 30, 2026
MSSM 0.00% 2,730 $ 12.285K Aug 31, 2026
DFAS 0.00% 412,653 $ 131.843K Nov 12, 2026
DXUV 0.00% 27,332 $ 8,732.57 Nov 12, 2026
DFAC 0.00% 213,298 $ 68.149K Nov 12, 2026
DFAU 0.00% 17,404 $ 5,560.58 Nov 12, 2026
DFUS 0.00% 20,150 $ 6,437.93 Nov 12, 2026